Please ensure Javascript is enabled for purposes of website accessibility

Is Pfizer's Buyout of Anacor Pharmaceuticals Enough to Move the Needle?

By George Budwell - May 16, 2016 at 11:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pfizer adds another key piece to its innovative products business today.

What: Shares of Anacor Pharmaceuticals (NASDAQ: ANAC) jumped by more than 55% today on the news that pharma giant Pfizer (PFE -0.23%) agreed to buy the company in an all-cash deal valued at around $5.2 billion. Pfizer's interest in Anacor reportedly centers around the drugmaker's non-steroidal ointment crisaborole that's currently under review with the FDA as a potential treatment for mild to moderate eczema.  

So what: While this buyout is small by Pfizer's standards, it could net the company its next blockbuster drug. Specifically, Pfizer's own estimates have pegged crisaborole's peak sales at close to $2 billion. Putting this figure into context, Pfizer's total annual revenue this year is forecast to come in at around $52 billion, showing that this experimental eczema treatment could make a meaningful impact on the drugmaker's top line going forward. 

Now what: Pfizer is apparently in the process of bulking up before splitting the company into two separate entities now that its attempts to move abroad have been thwarted by the U.S. Treasury. Keeping with this theme, Pfizer has also been rumored to have an eye on Medivation (MDVN) for its blockbuster prostate cancer drug Xtandi, although the asking price could end up being too steep for a deal to get done. After all, Medivation has already declined a $9.3 billion offer from Sanofi, implying that a bidding war may break out if Pfizer does enter the fray in earnest. 

The bottom line is that Pfizer is probably going to be on the hunt for more deals in the near term, driven by management and shareholder's collective desire to break the company apart in order to unlock the value of its red-hot innovative products business. So, this Anacor-Pfizer deal looks like a harbinger of things to come, which bodes well for valuations across the biopharma landscape moving forward. 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.31 (-0.23%) $0.12
Medivation, Inc. Stock Quote
Medivation, Inc.
MDVN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.